

# Policy Question

- Should vaccination with the Janssen COVID-19 vaccine (1-dose, IM) be recommended for persons 18 years of age and older under an emergency use authorization?

# Evidence to Recommendations Framework

## Summary: Work Group Interpretations

<p><b>Balance of consequences</b></p>	<p>Undesirable consequences <i>clearly outweigh</i> desirable consequences in most settings</p>	<p>Undesirable consequences <i>probably outweigh</i> desirable consequences in most settings</p>	<p>The balance between desirable and undesirable consequences <i>is closely balanced or uncertain</i></p>	<p>Desirable consequences <i>probably outweigh</i> undesirable consequences in most settings</p>	<p><b>Desirable consequences <i>clearly outweigh</i> undesirable consequences in most settings</b></p>	<p>There is insufficient evidence to determine the balance of consequences</p>
---------------------------------------	---	--	---	--	--	--

<p><b>Type of recommendation</b></p>	<p>We do not recommend the intervention</p>	<p>We recommend the intervention for individuals based on shared clinical decision-making</p>	<p><b>We recommend the intervention</b></p>
--------------------------------------	---	---	---

# ACIP Vote – Interim Recommendation

The Janssen COVID-19 vaccine is recommended for persons 18 years of age and older in the U.S. population under the FDA's Emergency Use Authorization.